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Abstract
Recent findings suggest that Notch signaling is active
in brain tumors and stem cells, and that stem cells or
cells with progenitor characteristics contribute to brain
tumor formation. These stem cells are marked by ex-
pression of several markers, including nestin, an
intermediate filament protein. We have studied how
the Notch signaling pathway affects nestin expression
in brain tumors. We find that Notch receptors and li-
gands are expressed in vitro and in human samples of
glioblastomas, the highest grade of malignant gliomas.
In culture, Notch activity activates the nestin promoter.
Activation of the Notch pathway also occurs in a glio-
blastoma multiforme mouse model induced by Kras,
with translational regulation playing a role in Notch
expression. Combined activation of Notch and Kras
in wild-type nestin-expressing cells leads to their ex-
pansion within the subventricular zone and retention
of proliferation and nestin expression. However, ac-
tivation of Notch alone is unable to induce this cel-
lular expansion. These data suggest that Notch may
have a contributing role in the stem-like character of
glioma cells.
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Introduction
Among tumors of the central nervous system (CNS), glio-
blastoma multiformes (GBMs) are the most aggressive
tumors with the poorest clinical prognosis. These tumors
consist of cells that are astrocyte-like but have complex
genetic makeup and expression patterns. One phenomenon
that can contribute to this complexity is the presence of
stem-like cells within the tumor and the activation of path-
ways that control cellular differentiation. Several groups
have been able to identify unique populations within GBMs
with stem cell properties [1–3]. However, which pathways
contribute to the formation of stem-like character and to
the dysregulation of differentiation remain to be fully de-
scribed. One marker that has been used to identify neural
stem cells is the intermediate filament protein nestin [4].
Nestin-expressing cells have the ability to differentiate into
multiple lineages, including neurons and glial cells within
the CNS—a characteristic found in glioma stem cells [5].
In trying to understand signaling events that regulate GBMs,
work in our laboratory has previously identified the Ras and Akt
pathways as being elevated in human GBMs, with a unique
synergistic effect on the translation of a subset of mRNA [6]. One
such target of increased translation is Notch1 mRNA. Notch
(Notch1–4 in mammals) is a family of transmembrane receptors
that regulate cell–cell signaling (reviewed in Artavanis-Tsakonas
et al. [7]). Notch ligands (Delta-like1, Delta-like3, and Delta-like4,
and Jagged1–2 in mammals) are also transmembrane pro-
teins and, when bound to Notch, act to expose the receptor to
proteolytic activation. Presenilins cleave Notch to generate a
Notch1 intracellular domain (NICD), which then translocates to
the nucleus to act as a transcriptional activator [8].
Activated Notch signaling appears particularly capable of
affecting both tumorigenesis and stem cell development. Notch
signaling was first shown to be inhibitory toward neurogenesis
and essential in maintaining a pool of undifferentiated stem
cells [9,10]. Deletion of Notch1 results in reduction in neural
stem cells; in presenilin/mutants defective inNotch signaling,
neural stem cells have reduced proliferative capacities [11].
Later studies have expanded the function of Notch to involve
important cell fate decisions throughout glial and neuronal de-
velopment. In the oligodendrocyte lineage, Notch activation
has been shown to suppress terminal oligodendrocyte differen-
tiation but also to support the specification of oligodendrocyte
precursors from the initial stem cell pool [12,13]. Notch signaling
can promote the specification of Muller glia in the rat retina
[14,15], radial glia in the telencephalon from cortical stem cells
[16], and astrocytes in the adult brain from hippocampal multi-
potent progenitors [17].
Notch signaling has been implicated in various steps
throughout tumorigenesis. Studies have identified the Ras
pathway, in particular, as being able to collaborate with the
Notch pathway to maintain and establish neoplastic pheno-
type [18,19]. In CNS tumors, Notch signaling components were
found to be deregulated in meningiomas [20], and its activity is
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observed to be critical in medulloblastomas [21,22]. In glio-
mas, Notch1 and its ligands Delta-like1, Delta-like3, and
Jagged1 have also been shown to be involved in glioma cell
survival, differentiation, and proliferation [23,24].
In this study, we investigated the role of Notch activation in
glioblastoma biology. We confirmed that Notch receptors
and ligands are expressed in human GBMs. This was also
true in a Kras-induced mouse GBM model. In these tumors,
Notch may participate in the transcription of specific gene
targets, particularly that of nestin, a neural progenitor
marker. The activation of nestin promoter by Notch was also
seen in cultures where Notch can directly act on the nestin-
regulatory region to activate its transcription. In vivo, we
found that combined activation of Notch and Kras signaling
was sufficient to generate lesions along the subventricular
zone (SVZ). These lesions expressed nestin and a marker
of proliferation, suggesting that they may be early precursor
lesions to tumorigenesis.
Materials and Methods
Tumor Samples
All human tissues were collected by the Memorial Sloan-
Kettering Institute tissue bank, snap-frozen, and stored at
80jC. Samples in liquid nitrogen were ground in mortar
and pestle. Protein was extracted from the powder through
lysis with T-per tissue extraction solution (Pierce Bio-
chemical, Rockford, IL) supplemented with miniTab protease
inhibitors (Boehringer Mannheim, Ingelheim, Germany),
30 mM sodium fluoride, and 1 mM sodium vanadate.
Microarray
Mouse tumors and arf/ cortex were dissected from
brains and frozen in liquid nitrogen. Tissue in liquid nitrogen
was ground to powder form by mortar and pestle. Probe
preparation and hybridization to chips were performed as
described before [6]. Briefly, RNA was prepared using Trizol
(Invitrogen, Carlsbad, CA) and Qiagen RNA Easy kit (Qia-
gen, Valencia, CA). cRNA was generated by in vitro tran-
scription using standard procedures. Probes were hybridized
to Affymetrics MOE430 chip (Affymetrics, Santa Clara, CA).
Chips were scanned by a Hewlett Packard GeneArray
Scanner (Hewlett Packard, Palo Alto, CA), and data were
collected by MicroArray Suite Software (Affymetrics). 5V Up-
stream promoter sequences were derived from ensembl.org.
Western Blot Analysis
Proteins were separated on sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred to nitrocel-
lulose membranes. The blocking reagent was 5% nonfat dry
milk in phosphate-buffered saline (PBS)–0.1% Tween 20.
Primary and secondary antibodies were prepared in the same
blocking reagent. Horseradish peroxidase (HRP)–conjugated
secondary antibodies were used at 1:1000 dilution and visu-
alized using ECL chemiluminescence (Amersham, Piscat-
away, NJ), hNotch1 1:50 [bTAN20; Developmental Studies
Hybridoma Bank (DSHB) (Iowa City, IA)], hNotch2 1:50
(C651.6DbHN; DSHB), mNotch1 1:500 (Neomarkers, Fre-
mont, CA), Delta-like1 1:500 (Santa Cruz Biotechnology,
Santa Cruz, CA), Jagged11:500 (Santa Cruz Biotechnology),
actin 1:1000 (Santa Cruz Biotechnology), anti-mouse HRP
(Boehringer Mannheim), and anti-rabbit HRP (Amersham).
DNA Plasmids
The construction of the retroviral vectors RCAS-Kras and
RCAS-Akt has been previously described [25,26]. The
RCAS(B) mouse Notch1 ICD plasmid was provided by
Dr. David Anderson and subcloned into RCAS(A). The
RCAS(B) control virus consists of noncoding (empty) or non-
productive virus plasmids. Rat Delta1 and rat Jagged1 cDNA
were provided by Dr. Gerry Weinmaster. The nestin-tk re-
porter plasmid was provided by Dr. Urban Lendahl [27,28].
Infection of tv-a Transgenic Mice and Tissue Processing
Generation of the transgenic mouse line that expresses
the RCAS receptor from the nestin promoter nestin tv-a
(Ntv-a) and Ntv-a arf/ mice has been previously described
[25,29]. Neonatal mice were injected in the cerebral hemi-
sphere with DF-1 chicken fibroblasts, producing appropriate
RCAS viruses on postnatal day 1. Mice were monitored and
then sacrificed when symptomatic or at the end of the study.
Brains were fixed in formalin, processed, embedded in par-
affin, and sectioned as previously described [30]. Chi-square
analysis was used to determine statistical significance.
In Situ Hybridization
Probe fragments were cloned into pDrive Cloning Vector
(Qiagen) using polymerase chain reaction (PCR) or restriction
digest. Probe lengths correspond to the following stretches of
cDNA, as demarcated by the following 5V and 3V sequences:
Notch probe: 5Vseq CAGCATGGCCAGCTCTGGTT,
3Vseq AGCAGCATCCACATTGTTCA
Hes1 probe: 5Vseq ATGCCAGCTGATATAATGGA, 3Vseq
TCAGTTCCGCCACGGCCTCC
rDelta1 probe: 5Vseq ATCACACCTGGAGCCGAGAG,
3Vseq GGCCGCTACTGTGAAGGTCC
rJagged1 probe: 5Vseq GGCCGGGGCGCCCCTTGAGC,
3Vseq GGCTGGGGTTTATCATGCCT.
Radioactive sense and antisense probes incorporating
[32P]UTPwere prepared using T7 or SP6 polymerase. Tissue
sections were deparaffinized and treated with proteinase K.
Slides were prehybridized with salmon sperm DNA and
hybridized overnight with probe in hybridization buffer (50%
formamide, 0.3 M NaCl, 20 mM Tris pH 8.0, 5 mM EDTA,
10 mM Na-phosphate, 10% dextran sulfate, 1 Denhardt’s
solution, and 500 mg/ml yeast tRNA) at 65jC. Slides were
washed, dipped in emulsion, exposed for 2 to 4 weeks, and
developed. Three to five tumors of each type were analyzed
with each probe set.
Image Analysis
For signal density analysis, paired dark-field images of
normal cortex and tumor regions were taken from the same
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slide using Zeiss Axioplan microscopes (Zeiss, Oberkochen,
Germany). All images were taken at fixed exposure and
resolution. Ten such paired images were generated for each
tumor type. Images were then processed on Metamorph
software (Metamorph, Sunnyvale, CA) to determine the area
of positive signal pixels. Areas of paired images were com-
pared (tumor to normal tissue), and statistical significance
was determined using t-test.
Immunohistochemistry (IHC)
Sections were processed for IHC as described previ-
ously, with antigen retrieval in citrate buffer with steam [31].
Antibody detection was visualized with peroxidase and
DAB processing (Vector, Burlingame, CA). The antibodies
used are as follows: 9E10 1:200 (human c-myc; Covance,
Princeton, NJ), nestin 1:1000 (PharMingen, San Diego,
CA), and proliferating cell nuclear antigen (PCNA) 1:1000
(Chemicon, Temecula, CA).
Luciferase Assay
Cells were transfected with plasmid containing pHES1-
luciferase, pCMV-RL (Promega, Madison, WI), and RCAS
expression vector (control, Notch, or Delta) using Fugene
(Roche, Nutley, NJ) according to the manufacturer’s instruc-
tions. Lysates were prepared, and luminescence was deter-
mined according to the Promega Dual-Luciferase Reporter
System protocol (Promega). Readings were performed with a
Turner Biosystems platereader. Firefly luminescence was
normalized to renilla luminescence. Hes1 reporter was sub-
jected to PCR with genomic DNA using the primers 5Vseq
ACGGGGTACCCTCAGGCGCGCGCCATTGGCC and 3Vseq
CCGAAGATCTGCTTACGTCCTTTTACTTGAC. The frag-
ment contains suspected CBF-1–binding sites. The fragment
was cloned into the PGL3-Basic Vector (Promega) using KpnI
and Bgl II.
-Galactosidase Assay
Cells were transfected with b-galactosidase reporter
constructs using Fugene according to manufacturer’s in-
structions. Two days after transfection, cells were fixed in
neutral-buffered formalin and washed in PBS. Cells were
then incubated at 37jC with a solution containing 1 mg/ml
X-gal, 20 mM K3Fe(CN)6, and 2 mM MgCl2 for 6 hours until
a blue precipitate was visible.
Results
Presence of Notch Receptors and Ligands in Primary
Human Glioblastomas
To determine whether Notch signaling could contribute
to gliomas and GBMs in particular, we compared astro-
cytic mixed astrocytic gliomas (World Health Organization
grades II and III), GBM expression profiles, and protein
levels. Previous work in our laboratory has described a
microarray experiment that identified genes overexpressed
in human gliomas [32]. This experiment compared 9 GBMs
and 10 non-GBM gliomas to pooled normal brain. Using this
database, we found that five of nine GBMs had a z 2-fold
expression in Jagged1 mRNA compared to normal brain,
whereas none of the non-GBM gliomas had any appreciable
difference in Jagged1 expression (Figure 1A). Unfortunately,
the probes for Notch1 and Delta-like1 were not represented
on the array used at the time. This suggested that Notch
ligand expression may contribute to glioblastoma formation.
To determine the protein levels of Notch receptors and
ligands in human tumors, a selection of primary human
tumors (GBMs and non-GBM gliomas) was subjected to
Western blot analysis (Figure 1B). We found Notch1 to be
expressed in all tumor types examined, whereas Notch2 was
expressed in a subset of tumors. Notch ligands Delta-like1
and Jagged1 were more selectively expressed in GBMs. The
coexpression of Notch and its ligands demonstrates that
autocrine or juxtacrine modes of activation are possible,
particularly in GBMs and but perhaps also in a smaller subset
of glial tumors.
Expression of Notch Receptors and Ligands in Mouse
Models of Tumors
Given the finding in human tumors, we investigated
whether this pattern of expression was also found in mouse
models of glial tumors, particularly comparing mouse models
of GBMs and oligodendrogliomas, a clinically less aggressive
form of glioma. In addition, because we know that translation
Figure 1. Notch receptor and ligand expression in human gliomas. (A)
Analysis of Jagged1 mRNA expression in glioblastomas (GBMs) and non-
GBM gliomas (NGGs) compared to normal brain. Data were derived from the
microarray of Tanwar et al. [32]. (B) Western blot analysis of Notch receptors
1 and 2, ligands Delta-like1 and Jagged1, and corresponding actin bands in
glial tumors.
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mayplay an important role inGBMs,we assessed differences
in expression in both mRNA and protein levels. Previously,
we have developed various mouse models of CNS tumors
generated through theRCAS/tv-a system. In this system, tv-a
receptor is expressed from a selective promoter by a trans-
gene, whereas an RCAS virus delivers oncogenes only into
these targeted cells [33]. Two tv-a transgenic lines have been
used in glioma modeling studies. One expresses tv-a from
the nestin promoter (Ntv-a), whereas the other expresses
tv-a from GFAP promoter (Gtv-a). The cell specificity of gene
transfer mediated by RCAS infection in these mice is deter-
mined by promoter-driven tv-a expression. After infection,
oncogenes are driven from the RCAS viral promoter and
are unaffected by the activity of the promoter driving the
tv-a transgene. The models include platelet-derived growth
factor B (PDGFB)-induced oligodendrogliomas in wild-type
mice and Kras-induced spindle gliomas and GBMs in arf-null
mice [29,30]. Of these tumors, the Ras and Akt pathways are
upregulated only in Kras-induced tumors and not in PDGFB
oligodendrogliomas [31]. Thus, theKras-inducedmodelmore
closely resembles human GBMs and has the potential to
exhibit similar translation effects. To investigate the expres-
sion of Notch pathway components, in situ and Western blot
analyses were performed on these different glioma subtypes.
It has been previously reported that Notch1 is expressed
in selected cells within the cerebellum in adult rat brain,
specially in the Purkinje cell layer [34]. We have confirmed
that we could obtain a similar pattern using our antisense
probe and had little backgroundwith the corresponding sense
probe control (Figure 2, A and B). We analyzed tumors
driven from Ntv-a mice where the cell of origin was nestin-
expressing. On in situ hybridization analysis, Notch1 mRNA
is overexpressed in both Ntv-a PDGF and Ntv-a Kras arf/
tumors compared to normal brain (Figure 2C). Because
translation may regulate Notch1 expression, defining relative
mRNA and protein levels may be important in understanding
Notch expression levels. To assess potential translation ef-
fect, we semiquantitatively determined relative mRNA ex-
pression levels by comparing in situ signal density in tumor
regions to control normal brain regions within the same
section (Figure 3A). Images were processed by Metamorph
software to determine the total positive signal image area in
each image. Tumor regions were then compared to normal
brain regions from the same slide. Kras-induced tumors had
Figure 2. Notch receptor and ligand expression in mouse glioma models. (A) Dark-field image of antisense Notch1 in situ hybridization, and hematoxylin and eosin
(H&E) image of the same section in the cerebellum. Positive signal corresponds to a previously described pattern for Notch1 [34]. (B) Notch1 sense strand in situ
hybridization control in tumor tissues. (C) Antisense in situ expression of Notch1, Delta-like1, Jagged1, and Hes1 mRNA in normal brain; PDGFB-induced
oligodendroglioma; and Kras-induced spindle GBMs.
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a 5.9-fold higher level of Notch1 signal compared to con-
trols, whereas PDGFB-induced oligodendrogliomas had
an 8.9-fold higher level (Figure 3B). Expression of Notch1
protein was also found to be higher in both tumor types
compared to normal brain (Figure 3C). However, Notch1
protein levels were much higher in Kras GBMs compared
to oligodendrogliomas even though in situ analysis re-
vealed that mRNA levels were relatively lower in Kras GBMs
than in PDGF oligodendrogliomas compared to normal brain
(5.9-fold vs 8.9-fold). This supports our previous finding that
Ras and Akt signaling pathways may selectively recruit
Notch1 mRNA into polyribosomes to be translated into
protein [6]. Substantially more active Akt and Ras signaling
pathways are found in Kras-induced GBMs compared to
PDGFB-induced oligodendrogliomas and may explain why
Notch1 protein levels are higher in our mouse models of
these tumors.
Delta-like1 and Jagged1, ligands of Notch receptors, were
found to be overexpressed by both in situ and Western blot
analyses in Kras-induced tumors (Figures 2C and 3C). In
PDGFB-induced oligodendrogliomas, these ligands are
either not elevated or only mildly elevated (Figures 2C and
3C). One common transcriptional target of Notch signaling is
HES1. We tested for HES1 expression in our mouse tumor
models and found it to be overexpressed in situ in Kras
arf/GBMs compared to normal tissues (Figure 2C). In
PDGFB oligodendrogliomas, HES1 expression was found
to be comparable to normal tissue or, perhaps, to be slightly
elevated on a cell-to-cell basis. These results suggest that, in
Kras-induced GBMs, the Notch pathway is active because
the receptor, ligand, and target are all expressed. In PDGFB-
induced oligodendrogliomas, the receptor appears to be
overexpressed; however, of the ligands and targets we
examined, only moderate levels were detected. There may
be some degree of Notch signaling through HES1 in oligo-
dendrogliomas, but the level of activation is much less com-
pared to that in Kras-induced tumors.
Notch Activation of Target Genes in Kras-Induced Tumors
Notch acts as a transcriptional activator by complexing
with the DNA-binding protein CBF-1, displacing repressive
factors and recruiting coactivators. Because one effect of
Notch signaling is activation of transcription, an expression
array analysismay reveal its function in Kras-induced tumors.
We compared the expression profile of two Kras-induced
tumors to the normal cortex from Ntv-a arf/ mice (Table 1
and Table W1). The list of genes upregulated contained a
wide range of proteins involved in various processes. In-
cluded in this list were some expected targets in Kras glioma-
genesis. For example, glial progenitor markers, including
vimentin, PDGFRa, and nestin, were increased. Ras signal-
ing components and matrix-degrading enzymes were also
increased.Of 828 genes upregulated by > 3-fold (P < .05), we
searched for CBF-1 consensus sites (YGTGGGAA) in the
5-kb 5V upstream promoter sequence in front of the tran-
scriptional start site using the annotation provided on www.
ensembl.org. Using this search, 136 genes were found to
have this motif and to be potential Notch target genes by
binding to CBF-1 (Table 1 and Table W1). Among this list of
genes are ones that have been implicated by other studies as
potential targets of Notch signaling, including cyclin D1 [35],
S100a10 [36], and a Snail family member [37]. Not identified
by this method but upregulated on the array and a potential
Notch target is the cyclin-dependent kinase inhibitor p21 [38].
One interesting target found by this search is nestin, an
intermediate filament protein that acts as a marker for neural
progenitor cells. Although the 5V upstream promoter plays a
role in modulating its expression, it is the nestin second intron
that directs expression in neural precursors [27,39]. Con-
served near the 3V end of the second intron of both human and
mouse nestins is a CBF-1–binding site (Figure 4A). We
tested whether Notch activation could activate transcription
Figure 3. Semiquantitative analysis of Notch1 mRNA and protein in PDGFB
and Kras tumors. (A) Sample dark-field images of Notch1 in situ in normal
and tumor regions of PDGFB and Kras tumors. (B) Image analysis of positive
signal regions in tumors. Positive pixel area (white grains in A) normalized to
positive pixel areas in control normal brain images (*P < .01). (C) Western
blot analysis of Notch1 and ligand expressions in PDGFB-induced
oligodendrogliomas and Kras-induced spindle GBMs.
1076 Notch Signaling Enhances Nestin Expression in Gliomas Shih and Holland
Neoplasia . Vol. 8, No. 12, 2006
Table 1. Selected List of Genes Upregulated By > 3-Fold in Kras arf/ Tumors Compared to arf/ Cortex.
GenBank Number Gene Name Protein Fold 1 Fold 2
Structural
NM_019390 Lmna Lamin A 7.0 4.9
BG970109 Lamb1-1 Laminin B1 subunit 1 7.5 12.1
AV147875 Vim Vimentin 12.1 16.0
AI413223 Nes Nestin* 18.4 17.1
Matrix-interacting
NM_008398 Itga7 Integrin a7* 3.7 4.9
NM_008872 Plat Plasminogen activator, tissue* 4.9 6.5
BM935811 Itga6 Integrin a6 5.7 3.5
U37029 Itgb1 Integrin b1 (fibronectin receptor b) 8.0 9.2
NM_013565 Itga3 Integrin a3 9.8 6.5
NM_008873 Plau Plasminogen activator, urokinase 18.4 29.9
NM_032007 Mmp1b Matrix metalloproteinase 1b (interstitial collagenase) 64.0 42.2
BC019135 Mmp12 Matrix metalloproteinase 12 97.0 111.4
NM_053110 Gpnmb Glycoprotein (transmembrane) nmb 119.4 59.7
Cell cycle
BC027026 Cdkn2c Cyclin-dependent kinase inhibitor 2C (p18) 4.0 6.1
X75483 Ccna2 Cyclin A2 4.9 4.6
AK007630 Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) 6.5 5.7
NM_007631 Ccnd1 Cyclin D1* 9.2 9.8
AU015121 Ccnb1 Cyclin B1 26.0 27.9
Signaling
NM_008008 Fgf7 Fibroblast growth factor 7 3.2 13.9
AW537708 Pdgfra Platelet-derived growth factor receptor, a polypeptide 3.7 4.3
BC013066 Dok1 Docking protein 1 4.9 9.2
NM_008696 Map4k4 Mitogen-activated protein kinase kinase kinase kinase 4 5.3 4.3
BM947855 Plk3 Polo-like kinase 3 (Drosophila) 5.7 4.3
NM_010517 Igfbp4 Insulin-like growth factor –binding protein 4 5.7 4.0
BF681826 Ralgps1 Ral GEF with PH domain and SH3-binding motif 1 7.0 8.6
L07264 Hbegf Heparin-binding EGF-like growth factor 7.5 12.1
NM_007484 Rhoc Ras homolog gene family, member C 8.0 11.3
NM_007900 Ect2 ect2 oncogene 8.6 13.9
S69114 Tgfbr2 Transforming growth factor, b receptor II 9.2 19.7
NM_007568 Btc b-Cellulin, epidermal growth factor family member 9.8 16.0
AV367068 Dhh Desert hedgehog* 10.6 9.8
NM_133914 Rasa4 RAS p21 protein activator 4 26.0 11.3
NM_011950 Mapk13 Mitogen-activated protein kinase 13 45.3 36.8
Transcription and translation
BM200591 Eif1a Eukaryotic translation initiation factor 1A 3.0 3.0
BC013717 Etf1 Eukaryotic translation termination factor 1 3.2 3.7
BM120823 Eif4e2 Eukaryotic translation initiation factor 4E member 2 4.3 4.6
BC012674 Ptrf Polymerase I and transcript release factor* 4.9 4.0
NM_133626 Rrbp1 Ribosome-binding protein 1* 9.8 7.0
Transcription factors
AI746342 Stat6 Signal transducer and activator of transcription 6 3.7 4.3
BC006728 Myc Myelocytomatosis oncogene 4.0 3.5
NM_011415 Snai2 Snail homolog 2 (Drosophila)* 4.6 26.0
BF017589 Sin3b Transcriptional regulator, SIN3B (yeast)* 4.6 4.6
BC005686 Elk3 ELK3, member of ETS oncogene family 6.1 7.5
AB012278 Cebpb CCAAT/enhancer binding protein (C/EBP), b 8.6 6.1
NM_007855 Twist2 Twist homolog 2 (Drosophila) 9.2 10.6
NM_009821 Runx1 Runt-related transcription factor 1 9.8 10.6
U34245 Fosl1 Fos-like antigen 1 11.3 6.1
BC003778 Tcfap2c Transcription factor AP-2, g 12.1 32.0
NM_033597 Myb Myeloblastosis oncogene 14.9 6.5
BC019946 Atf3 Activating transcription factor 3 16.0 24.3
Other
BB829652 Nedd1 Nedd1* 3.0 4.3
M12573 Hspa1b Heat shock protein 1B 5.3 6.1
BC008152 Casp1 Caspase 1 6.5 13.9
AF220524 Dnmt3l DNA (cytosine-5)-methyltransferase 3– like* 6.5 18.4
BC025083 Glipr1 GLI pathogenesis-related 1 (glioma) 8.0 13.0
NM_009112 S100a10 S100 calcium-binding protein A10 (calpactin)* 8.0 7.0
NM_009892 Chi3l3 Chitinase 3– like 3 362.0 157.6
Folds 1 and 2 represent fold changes in two tumors compared to the cortex.
*A gene that has a potential CBF-1–binding site in its 5-kb 5V upstream promoter sequence.
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through this element. The human nestin second intron en-
hancer element linked to a tk minimal promoter is sufficient
to replicate the neural expression pattern for nestin [28].
This enhancer–promoter combination was used to drive
the expression of two reporter genes -galactosidase and
luciferase. Nestin reporters were tested in U251 glioma cell
lines in the presence and in the absence of NICD expression.
This form of Notch is equivalent to the proteolytically pro-
cessed receptor, a constitutively active isoform [8]. We found
that NICD could activate the promoter using either reporter. In
the b-galactosidase assay, U251 cells cotransfected with
NICD turned blue, whereas those cotransfected with empty
vector did not (Figure 4, B and C). NICD also activated the
luciferase reporter 4.8-fold compared to controls (Figure 4D).
These data suggest that Notch may act directly to activate
nestin expression in progenitor cells or glioma cells.
To assess whether activation of the Notch pathway corre-
lated with nestin expression in vivo, we stained Ntv-a Kras
arf/ tumors and Ntv-a PDGFB tumors for nestin expres-
sion. In Kras-induced spindle-like tumors where the Notch
pathway is active, nestin is expressed throughout the tumor
(Figure 4E ). However, in PDGFB-induced oligodendroglio-
mas where HES1, Delta1, and Jagged1 are not elevated to
the same degree, nestin is not clearly expressed by tumor
cells (Figure 4F ). This shows that in vivo nestin expression
correlates with activation of the Notch pathway.
Figure 4. Notch1 activation of the nestin second intron element. (A) Alignment of human and mouse Nes second intron segments. Boxed regions indicate potential
CBF-1–binding site. Numbering based on GenBank sequences: human AF004335 and mouse AY438043. (B and C) Assay for -galactosidase activity. U251 cells
were transfected with a nestin –-galactosidase reporter, along with either (B) empty vector or (C) NICD-expressing vector. (D) Luciferase assay of U251 cells
transfected with nestin reporter along with either empty vector or NICD-expressing vector (*P < .01). (E) Nestin IHC in Kras-induced spindle tumor in Ntv-a arf/
mouse. (F) Nestin IHC in PDGFB-induced oligodendroglioma.
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Notch1 Activation Can Cooperate with Kras
to Form Progenitor-Like Lesions
To establish the effect of Notch1 activation on glial tumors,
we subcloned a myc-tagged mouse NICD isoform into the
RCAS(A) retroviral system. The construct was tested for
functionality by the ability to activate the Hes1 promoter
(Figure 5A). To determine whether the expression of NICD
in nestin-positive glial progenitors would be sufficient to
induce tumorigenesis, we infected 39 Ntv-a mice with either
RCAS NICD virus or RCAS NICD virus with an empty RCAS
virus on postnatal day 1 and observed them for symptoms.
We analyzed 21 mice up to 12 weeks and 18 mice up to
24 weeks. None of these developed any signs of tumor, and
histologic analysis of the brains yielded normal-appearing
results (Figure 5B). To determine whether Notch signaling
could cooperate with other oncogenes, we coinfected NICD
Figure 5. Activated Notch and Kras can induce lesions in Ntv-a– targeted mice. (A) HES1 promoter luciferase assay with empty plasmid control or RCAS NICD
transfection. (B) Table of lesion incidence in NICD/NICD + control virus, NICD + Akt, and NICD + Kras infections of Ntv-a mice (*P < .05). NICD + Kras compared to
NICD/NICD + control virus. (C) H&E of NICD + Kras lesion located in the SVZ. (D) Kras + NICD lesion H&E, myc tag IHC of myc-tagged NICD, nestin IHC, and
PCNA IHC. (E) HA Western blot analysis of cell lysates from rDelta1-HA– transfected and control-transfected cells. (F) IHC of HA (rDelta1) and nestin expression
from a Kras + rDelta1-HA–generated tumor in Gtv-a arf/ mice.
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virus with a virus carrying either activated Akt or Kras—
oncogenes previously identified to contribute to glial tumori-
genesis [25]. Furthermore, the delivery of these oncogenes
alone in a wild-type background is insufficient to generate
tumors or lesions in this mouse model [25]. The combina-
tion of NICD and Akt failed to generate any distinguishing
abnormalities in 25 tested mice analyzed up to 24 weeks.
However, the combination of NICD and Kras produced peri-
ventricular lesions in 9 of 90 infected mice. Twenty-nine
mice were analyzed up to 12 weeks, and 61 mice were
analyzed up to 24 weeks. Regardless of the age of the mice
in which they were found, lesions remained small and limited
to the SVZ without progressing to tumors or larger lesions
(Figure 5C). This incidence of lesion formation was sta-
tistically significant (P < .05) when compared to mice in-
fected with RCAS NICD virus alone or combined with a
control RCAS virus. These lesions were then analyzed for
immunohistochemical markers (Figure 5D). They are positive
for themyc tag on the NICD, indicating effective viral delivery,
and are also positive for nestin and PCNA, indicating that
cells were in active cell cycles. This result confirms in vivo the
potential for nestin to be a direct Notch transcriptional target.
This also suggests that Notch activation can cooperate
with Kras to produce lesions that retain stem-like character
by their location in the SVZ, continued proliferation, and
progenitor marker expression. Nestin expression is main-
tained either through Notch’s direct action on its promoter
or through Notch’s effect on maintaining an undifferentiated
state in nestin-positive progenitors.
Ntv-a mice support gene transfer to nestin-expressing
cells; in this case, Notch activity may simply maintain nestin
expression. We next used Gtv-a mice to determine the ability
of Notch activation to drive nestin expression in tumors
derived from a GFAP-expressing cell of origin, a more differ-
entiated cell type that has already lost nestin expression. We
cloned an HA-tagged version of rat Delta1 (a ligand for Notch
receptor) into the RCAS vector and assessed its expression
using Western blot detection of the HA tag in Ntv-a mouse–
derived glial cells (Figure 5E ). We then infected Gtv-a arf/
mice with RCAS-Kras, RCAS-rDelta1-HA, or a combination
of the two. Gtv-a arf/ mice express the viral-targeting
receptor on GFAP-positive cells, and RCAS-mediated Kras
oncogene delivery to these cells induces a similar spindle
tumor with moderate nestin expression, as seen with Ntv-a
arf/ mice [29]. These tumors have abundant Notch1 ex-
pression, as determined by in situ analysis. Expression of
rDelta1-HA alone in these mice was insufficient to induce
tumors. Mice infected with a combination of RCAS-Kras and
RCAS-rDelta1-HA developed tumors and were sacrificed
when symptomatic or at 12 weeks. These tumors were then
analyzed for HA and nestin expression. HA-staining regions
are composed of Kras-driven tumors that have additional
Notch activation by the expression of rDelta1. In analyzing the
five large tumors that developed, in regions where Kras alone
was expressed (with no HA staining), nestin expression
was intermediate throughout (Figure 5F ). However, nestin
expression was markedly elevated where rDelta1 was co-
expressed (as determined with positive HA staining) with
Kras (Figure 5F ). This demonstrates that elevated Notch
signaling upregulates nestin expression in glial tumors, even
from a GFAP-expressing cell of origin, and can collaborate
with Kras signaling to alter tumor phenotype.
Discussion
Our study demonstrates that Notch signaling can play impor-
tant roles in glial tumor development, particularly in promoting
nestin expression that may contribute to stem cell potential.
We were able to identify Notch receptors and ligands in
human glial tumors, suggesting that juxtacrine or autocrine
modes of activation are possible—a situation that most often
occurs in GBMs, the highest grade of glial tumors. Previous
results have indicated higher Notch1 mRNA in grade II to
grade III astrocytomas than in GBMs, no significant elevation
of Delta-like1 mRNA in astrocytomas and GBMs, and eleva-
tion of Jagged1 in only a subset of GBMs [23]. Our results
agree with this previous report on the elevated level of
Jagged1 in a subset of GBMs. However, at the protein level,
we observed similar levels of Notch1 receptor in human glial
tumors and higher ligand levels in GBMs. The lack of corre-
lation between mRNA and protein levels is consistent with
previous reports showing that Notch1 is one mRNA that is
translationally regulated through its recruitment into poly-
ribosomes by signaling pathways known to be active inGBMs
[6]. In this study, we observed a similar finding in mouse
tumors with elevated Notch1 protein in Kras-induced GBMs,
where Ras and Akt pathways are significantly elevated.
Thus, equivalent mRNA levels may lead to differing amounts
of protein. We have also identified Notch2 protein to be
expressed in selected GBMs. Thus, our results add to the
growing literature supporting the importance of Notch signal-
ing in the formation of human GBMs.
In our mouse glial tumor models, we found that, in Kras-
induced GBMs, Notch1 receptor, Delta-like1, and Jagged1
are upregulated, accompanied by increased transcription of
HES1, a common Notch transcriptional target. The coop-
erative nature of activated Notch and Kras signaling was
additionally observed with the ability of these two genes
combined to generate lesions located in the SVZ, the location
of neural stem cells. The cells in these lesions continue to
express a proliferation marker and also nestin, much as
stem-like cells do. The ability of Notch to sustain the expres-
sion of the progenitor marker nestin may have a direct effect
on transcription by Notch at the nestin second intron en-
hancer element. Based on these findings, Notch activation
appears capable of promoting or sustaining nestin expres-
sion and the stem-like character of SVZ cells.
Given the diverse roles that the Notch pathway plays in
normal glial development, parallels between development
and tumor formation may be seen. As in development,
persistent Notch activation may be a means to keep cells in
a more undifferentiated progenitor state. It is believed that
cancer stem cells may be the source of tumor cells and that
SVZ is thought to be the origin of neural stem cells in the
cerebrum [40]. The periventricular lesions seen with com-
bined Notch and Kras infections in wild-type mice may be a
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reflection of this aspect of Notch’s function. In normal devel-
opment, nestin-positive cells migrate from the SVZ into the
brain on postnatal day 0 and are limited to a small zone of
periventricular cells in the adult brain [41]. By activating the
Notch andRas pathways in nestin-positive progenitors, these
cells appear capable of continued proliferation in adult mice
in the SVZ as if they have been prevented from proceeding
through a normal differentiation pathway.
In Kras-generatedGBMs, the activation of theMAPkinase
Erk and Akt pathways may affect protein translation. Thus,
compared to PDGFB-generated oligodendrogliomas, Kras-
induced GBMs produce more Notch proteins from relatively
similar amounts of Notch mRNA. The expression of Notch
ligands Delta1 and Jagged1 appears to be regulated by tran-
scriptional mechanisms that upregulate expression in Kras
tumors and not in PDGFB tumors. The coexpression of ligand
and receptor in Kras-induced GBMs may be responsible
for juxtacrine Notch signaling that can maintain progenitor
characteristics. Therefore, nestin expression is correlated
with Kras-induced GBM-like tumors and not with PDGFB-
induced oligodendrogliomas. In PDGFB-generated oligoden-
drogliomas, the Notch1 receptor is overexpressed, but the
ligands and Hes1 target are either minimally expressed or
at levels slightly higher than that in normal brain. This,
however, does not exclude Notch function from these tu-
mors. There are three Delta-like isoforms and two Jagged
isoforms, in addition to a newly identified ligand F-contactin
that has been shown to have specific effects on oligoden-
drocytes [42]. Alternatively, the lower level of receptor and
ligand expression seen in Western blot analysis may still be
sufficient for signaling.
Inhibition of Notch activity may be useful for glioma
therapy. One possible target is presenilin g secretase, which
acts to cleave and release Notch from membranes. The
combination of a Notch inhibitor and Ras inhibitor may be
particularly effective because these pathways seem to work
synergistically to induce lesions and to sustain Ras effects.
Further studies that elucidate themolecular mechanisms and
specific targets of Notch signaling, particularly ones that
distinguish its multiple functions, will also bring greater insight
into glioma biology.
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Table W1. Genes with Potential CBF-1–Binding Sites in the 5-kb 5V Upstream Promoter Sequence from the Transcriptional Start Site (as Defined By
ensembl.org).
Genes with Potential CBF-1–Binding Sites
Adamts1 Cma2 Hist1h4i Ncf4 S100a4
Ahnak Csf2rb1 Hist2h2aa1 Nedd1 Saa3
Akap12 Ctsz Hist2h3c1 Nes Samhd1
Angptl4 Cxcl4 Hist3h2a Niban Sdfr2
Anxa1 Dhh Hmga1 Nid2 Serpine1
Anxa4 Dnase1l1 Ibsp Nmt2 Sgol1
Ap2b1 Dnmt3l Icsbp1 Nusap1 Sin3b
Aqp1 Emilin1 Igsf6 Ostf1 Slc16a3
Baiap2l1 Emp1 Il1r2 P4hb Slc20a2
BC027061 Ezh2 Itga7 Pcolce Slc25a24
Bfsp1 F7 Itpr3 Pcolce2 Slfn1
C1qb Fabp4 Kdelr2 Plat Snai2
C1qtnf1 Fblim1 Kdelr3 Plaur Spata6
Calca Gbp2 Kif4 Plp2 Spp1
Cald1 Gem Lama4 Podxl Stk17b
Car13 Glipr2 Lcp1 Ppap2c Stk3
Cask Gpr35 Lgals3 Prlpb Tagln2
Ccl24 Guca1a Lgals7 Ptpn6 Tax1bp3
Ccnd1 H2-Aa Lmnb1 Ptrf Tcfec
Cd244 H2-Ab1 Loxl1 Ptx3 Tfpi2
Cd274 Hdlbp Ltb4dh Pxn Thbs1
Cd300lf Hist1h2ad Mcpt1 Rgs18 Timp1
Cd9 Hist1h4f Myh9 Rrbp1 Tnfaip2
Cflar Hist1h4h Myo1c S100a10 Ugt1a2
